Rapid-acting insulin analogues: No additional benefit for children with type 1 diabetes

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin. Certainly, there is no proof of additional benefit from the available results from clinical trials of maximum one year duration. Link:  http://www.iqwig.de/

Read the whole article on Science Blog

More from Science Blog